Regression of electrocardiographic left ventricular hypertrophy following treatment of primary hyperaldosteronism.
The electrocardiograms (ECGs) of a series of 34 patients with primary hyperaldosteronism (PHA), 17 treated surgically (group I) nine treated medically (group II) and eight treated with/by both surgery and drug therapy (group III) were analysed to determine whether the treatment of PHA resulted in an improvement in the ECG changes of left ventricular hypertrophy (LVH) and also whether there was a difference in this improvement between medically and surgically treated patients. There was a significant reduction of blood pressure in the group as a whole (186/111 to 141/95 mmHg, P less than 0.001) and within each of the treatment groups (group I 183/108 to 137/98 mmHg, group II 188/112 to 147/93 mmHg, group III 193/115 to 144/92 mmHg). This reduction within each group was of a similar magnitude. There were reductions in both precordial voltages (SV1 + RV5) from 3.68 mV to 2.79 mV (P less than 0.01) and in the number of patients with ECG LVH from 15 to 8 (P less than 0.05). Again the reductions were of similar magnitude in each of the groups: group I 3.78 to 2.77 mV, group II 3.78 to 2.84 mV, group III 3.39 to 2.77 mV. Thus the improvement in blood pressure achieved by the treatment of PHA is accompanied by a reduction in precordial voltages and the number of patients with ECG-LVH. This improvement is independent of the type of treatment used.
Pringle
S D
SD
Department of Medical Cardiology, Royal Infirmary, Glasgow, UK.
Macfarlane
P W
PW
Isles
C G
CG
Cameron
H L
HL
Brown
I A
IA
Lorimer
A R
AR
Dunn
F G
FG
D000328:Adult; D000450:Aldosterone / Q000097:blood; D001794:Blood Pressure; D006332:Cardiomegaly / Q000209:etiology / Q000503:physiopathology*; D004562:Electrocardiography; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D008875:Middle Aged
D000450:Aldosterone